Endometriosis: novel etiopathogenetic concepts and clinical perspectives
Mario Vignali1, Mirco Infantino, Roberta Matrone
1IRCCS Istituto Auxologico Italiano, Milan, Italy. mario.vignali@inimi.it
Objective:
To discuss current ideas about therapy for endometriosis derived from new observations generated by using molecular biology techniques and in vivo animal models of disease.
Method(S):
The MEDLINE database was reviewed for English-language articles on new drugs that affect the endocrine or immunologic system, the possibility that endometriosis has multiple forms, and the association of endometriosis with cancer. Specific attention was given to in vivo studies in animals or humans.
Conclusion(S):
Among the novel potential candidate drugs, aromatase inhibitors and raloxifene should be considered for treatment of postmenopausal women with endometriosis. Notable observations have emerged from studies of immunomodulators and antiinflammatory agents in animal models of disease. These findings must be confirmed in women. The histogenesis of ovarian endometriomas is still unclear, thus limiting new experimental approaches to this form of disease. Given the low but established risk for malignant transformation of endometriosis, efforts should be directed toward identification of susceptibility loci for the disease and its potential transformation into cancer.
Insights
Novel therapies for endometriosis, including aromatase inhibitors and raloxifene, show promise for postmenopausal women. Research into immunomodulators and anti-inflammatory agents in animal models requires human confirmation for endometriosis treatment.
Area of Science:
- Reproductive Medicine
- Molecular Biology
- Immunology
Background:
- Endometriosis is a complex gynecological condition with unclear origins.
- Current therapeutic strategies are limited, necessitating novel approaches.
- Emerging research utilizes molecular biology and animal models to understand disease mechanisms.
Purpose of the Study:
- To review current therapeutic concepts for endometriosis.
- To integrate findings from molecular biology and animal models into treatment strategies.
- To explore novel drug candidates and their potential applications.
Main Methods:
- Literature review of MEDLINE database for English-language articles.
- Focus on endocrine and immunologic system-affecting drugs.
- Inclusion of in vivo studies in animal models and humans.
Main Results:
- Aromatase inhibitors and raloxifene are potential candidates for postmenopausal endometriosis.
- Immunomodulators and anti-inflammatory agents show promise in animal models.
- The histogenesis of ovarian endometriomas remains an area requiring further investigation.
Conclusions:
- Novel drug candidates warrant consideration for endometriosis treatment in specific populations.
- Findings from animal models need validation in human studies.
- Further research is crucial for understanding endometriosis pathogenesis and malignant transformation risk.
